Introducing 'ChargeSMEDDS'

Enbiocell discussed collaboration on oral peptide delivery technology with global pharmaceutical companies at BioJapan 2026, Asia's largest biotech partnering event.

Enbiocell Discusses Collaboration With Global Pharma Giants at BioJapan View original image

On October 22, Enbiocell said it held a series of meetings at the event in Yokohama, Japan, with two global pharmaceutical companies, Japanese pharmaceutical and biotech companies, and Korean companies including CJ CheilJedang, showcasing its proprietary oral peptide delivery platform, ChargeSMEDDS.


With the strategic alliance department of one pharmaceutical company's Japan-based R&D organization, it discussed potential collaboration in formulation and drug delivery systems (DDS). The discussions focused on the technology's ability to enable oral absorption of peptides without permeation enhancers, its distinguishing features, and directions for joint research. With CJ CheilJedang, the discussions covered a broad range of opportunities, including not only oral formulations but also dermocosmetics using Enbiocell's other platform technologies and delivery-vehicle ingredients for health functional foods.


ChargeSMEDDS is a nano-delivery platform based on a self-microemulsifying drug delivery system (SMEDDS). The technology converts peptide and protein medicines, which have primarily been administered by injection, into oral medicines. A key feature is that it does not rely on the permeation enhancer SNAC used in existing oral peptide products. Enbiocell is currently co-developing an oral GLP-1 treatment with a Korean biopharmaceutical company, with the goal of submitting an investigational new drug (IND) application in 2027. It has completed an international patent (PCT) application for the core technology.



Jeong Hoseop, CEO of Enbiocell, said, "With the obesity and metabolic disease treatment market growing rapidly, I saw firsthand that global pharmaceutical companies have very strong interest in technologies that convert injectable medicines into oral ones. We will turn the discussions initiated at BioJapan into concrete joint research and technology transfer outcomes, and demonstrate the competitiveness of Korean DDS technology in the global market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing